Ask this question - if Australian decision-makers can disregard the human impact of delays in reimbursed access to health technologies, why should they be excused from considering the broader consequences? …
Challenging headlines are the natural consequence of disrupting a very stale debate
April 15, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
UCB welcomes new TGA registration for monoclonal antibody
April 16, 2025 - - Latest News -
Investors appear comfortable as Trump administration says pharma tariffs coming
April 16, 2025 - - Latest News -
Astellas Pharma Australia appoints new head of medical affairs
April 16, 2025 - - Latest News -
Challenging headlines are the natural consequence of disrupting a very stale debate
April 15, 2025 - - Latest News -
US FDA announces plan to phase-out animal testing in drug development
April 15, 2025 - - Latest News -
ViiV Healthcare announces the recipients of 2024 Positive Action Community Grants
April 15, 2025 - - Latest News -
Medicines Australia appoints new senior policy executive
April 15, 2025 - - Latest News